Carlson Capital’s Coherus Oncology CHRS Stock Holding History

Carlson Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-23,000	Closed	-$373K	–	175
2020 Q1	$373K	Sell	23,000 -64,500	-74%	-$1.19M	0.01%	194
2019 Q4	$1.57M	Buy	87,500 +29,276	+50%	+$540K	0.03%	204
2019 Q3	$1.18M	Sell	58,224 -96,776	-62%	-$1.93M	0.02%	209
2019 Q2	$3.43M	Sell	155,000 -340,365	-69%	-$5.91M	0.05%	219
2019 Q1	$6.76M	Sell	495,365 -1,224,171	-71%	-$16.3M	0.12%	189
2018 Q4	$15.6M	Buy	+1,719,536	New	+$19.9M	0.24%	129
2017 Q4	–	Sell	-728,419	Closed	-$9.72M	–	225
2017 Q3	$9.72M	Sell	728,419 -290,064	-28%	-$3.84M	0.17%	165
2017 Q2	$14.6M	Sell	1,018,483 -188,318	-16%	-$3.62M	0.21%	147
2017 Q1	$25.5M	Buy	1,206,801 +806,139	+201%	+$19.8M	0.32%	99
2016 Q4	$11.3M	Buy	+400,662	New	+$11.2M	0.14%	177

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlson Capital's CHRS Position: Q2 2020 in Review

Carlson Capital sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 23,000 shares — an estimated $373K sold.

Carlson Capital first reported a position in CHRS in Q4 2016 and held it in 10 quarters. The position peaked at $25.5M in Q1 2017. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Carlson Capital reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Carlson Capital sold 23,000 Coherus Oncology shares in Q2 2020, an estimated $373K.
Carlson Capital first reported a position in Coherus Oncology in Q4 2016 and held it in 10 quarters.
Carlson Capital's Coherus Oncology position peaked at $25.5M in Q1 2017.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Carlson Capital's 13F filing for Q2 2020, filed 14 Aug 2020.